{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:44:05Z","timestamp":1777934645859,"version":"3.51.4"},"reference-count":23,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Clinical practice guidelines (CPGs) recommending palonosetron for the prevention and management of chemotherapy-induced nausea and vomiting (CINV) were adapted for use at our institution. Palonosetron was restricted for use in patients experiencing breakthrough CINV and receiving highly emetogenic chemotherapy (HEC) or undergoing stem cell transplant conditioning and in patients with refractory CINV receiving HEC. Given the significant cost of palonosetron, we aimed to determine the proportion of chemotherapy blocks where palonosetron use was discordant with the institutional policy or source CPG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective review of the health records of patients who received palonosetron between 1 July 2019 and 30 June 2020 was undertaken. Details of palonosetron use, antiemetic regimen and the date and time of each vomit during the acute and delayed phases were collected for each chemotherapy block where palonosetron was given. Discordance with the institutional policy and the source CPG was determined by assessing the indication for palonosetron and the dose. In the subset of chemotherapy blocks where information regarding vomiting episodes was available, the extent of acute phase chemotherapy-induced vomiting (CIV) control was reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four hundred thirty-eight chemotherapy blocks, representing 122 patients (mean age 9 years), receiving 595 palonosetron doses were included. Palonosetron use was discordant with institutional policy during most (72%; 314\/438) of the chemotherapy blocks analyzed. However, palonosetron use was concordant with the source CPG during most chemotherapy blocks (74%; 326\/438). Complete CIV control during the acute phase was observed in 66% (195\/295) of chemotherapy blocks where palonosetron was given, irrespective of concomitant antiemetics administered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The majority of palonosetron use at our institution was discordant with institutional policy, but concordant with the source CPG. Our institutional policy has since been updated to be more aligned with the source CPG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552241233489","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T01:34:10Z","timestamp":1709256850000},"page":"251-255","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Palonosetron in pediatric patients: A single-center, retrospective evaluation of policy and clinical practice guideline discordance"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5176-9125","authenticated-orcid":false,"given":"Meredith","family":"Ames","sequence":"first","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada"},{"name":"The Hospital for Sick Children"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Patel","sequence":"additional","affiliation":[{"name":"The Hospital for Sick Children"},{"name":"Pediatric Oncology Group of Ontario, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7699-1061","authenticated-orcid":false,"given":"L Lee","family":"Dupuis","sequence":"additional","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada"},{"name":"The Hospital for Sick Children"},{"name":"The Hospital for Sick Children"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Koo","sequence":"additional","affiliation":[{"name":"The Hospital for Sick Children"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2008.04.007"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.01.028"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2012.000816"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4259-1"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.019448"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26542"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01296"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24508"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30001"},{"key":"e_1_3_2_11_2","unstructured":"Pediatric Oncology Group of Ontario (POGO). Quick Review Summary: Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric patients. 2021 Jan https:\/\/www.pogo.ca\/wp-content\/uploads\/2021\/01\/Acute-AINV_Quick-Summary_15Jan2021_C.pdf"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00520-3"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26815"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1568988"},{"key":"e_1_3_2_15_2","unstructured":"Dupuis LL Alexander S Ali M et al. Prevention of Chemotherapy or Radiotherapy-induced Nausea and Vomiting. The Hospital for Sick Children Departmental Guidelines (version 1) (2017)."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25955"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23114"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.4789"},{"key":"e_1_3_2_19_2","unstructured":"Ettinger DD Berger MJ Anand S et al. Antiemesis. NCCN Clinical Practice Guidelines in Oncology. Version 1.2021 (2020) http:\/\/nccndd.qitian-med.tech\/nccn-his\/%E6%AD%A2%E5%90%90\/%E6%AD%A2%E5%90%902021.1%E7%89%88.pdf"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3332-x"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s43058-021-00200-2"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.2921"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds021"},{"key":"e_1_3_2_24_2","unstructured":"Dupuis LL Alexander S Ali M et al. Prevention of Chemotherapy or Radiotherapy-induced Nausea and Vomiting. The Hospital for Sick Children Departmental Guidelines (version 1) (2022)."}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241233489","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241233489","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241233489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:29:33Z","timestamp":1777688973000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241233489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1177\/10781552241233489"],"URL":"https:\/\/doi.org\/10.1177\/10781552241233489","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]}}}